These pivotal clinical trials established doxorubicin, cyclophosphamide, paclitaxel and trastuzumab (ACTH) and non-anthracycline based regimens such as docetaxel, carboplatin and trastuzumab (TCH) as standard of care adjuvant treatment for HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.